Evidence map›Paper›PMID 40501644›Full record

ArticlebioRxiv : the preprint server for biology2025

Human Cytomegalovirus UL78 is a Nuclear-Localized GPCR Necessary for Efficient Reactivation from Latent Infection in CD34

Samuel Medica, Nicole L Diggins, Michael Denton, Rebekah L Turner, Lydia J Pung, Adam T Mayo, Jennifer Mitchell, Luke Slind, Linh K Nguyen, Teresa A Beechwood and 6 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Samuel MedicaVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.ORCID 0000-0002-3611-3715
Nicole L DigginsVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Michael DentonVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Rebekah L TurnerVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Lydia J PungVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Adam T MayoVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Jennifer MitchellVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Luke SlindVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Linh K NguyenVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Teresa A BeechwoodVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Gauthami SulgeyVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Craig N KreklywichVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Daniel MalouliVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Patrizia CaposioVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Daniel N StreblowVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Meaghan H HancockVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.ORCID 0000-0003-2945-0147

Funding

Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
The Administrative CoreP01AI127335 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI Patrizia Caposio · 2017 to 2026
$24.6M
Molecular Aspects of Cytomegalovirus LatencyR37AI021640 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI HANCOCK, MEAGHAN H · 2018 to 2024
$4.0M
Interdisciplinary Training in Microbial Pathogenesis and ImmunologyT32AI170496 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI Patrizia Caposio, Scott M Landfear · 2023 to 2026
$1.5M
NIAID NIH HHS P01 AI127335NIAID NIH HHS R37 AI021640NIAID NIH HHS T32 AI170496NIH HHS P51 OD011092
6 · The paper itself

Abstract

Human cytomegalovirus (HCMV) is a ubiquitous pathogen that persists throughout the lifetime of the host due in part to the establishment of latency in CD34

Identifiers

PMID40501644
PMCPMC12157656

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.